A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms IBUKI
- Sponsors Bayer
- 06 Feb 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Mar 2017.
- 28 Mar 2016 New trial record